KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Amortization - Intangibles: 2022-2024

Historic Amortization - Intangibles for Halozyme Therapeutics (HALO) over the last 3 years, with Dec 2024 value amounting to $71.0 million.

  • Halozyme Therapeutics' Amortization - Intangibles changed negligibly% to $17.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $71.0 million for FY2024, which is 3.69% down from last year.
  • Halozyme Therapeutics' Amortization - Intangibles amounted to $71.0 million in FY2024, which was down 3.69% from $73.8 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Amortization - Intangibles ranged from a high of $73.8 million in FY2023 and a low of $43.1 million during FY2022.
  • In the last 3 years, Halozyme Therapeutics' Amortization - Intangibles had a median value of $71.0 million in 2024 and averaged $62.7 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Amortization - Intangibles soared by 70.98% in 2023, and later declined by 3.69% in 2024.
  • Over the past 3 years, Halozyme Therapeutics' Amortization - Intangibles (Yearly) stood at $43.1 million in 2022, then soared by 70.98% to $73.8 million in 2023, then fell by 3.69% to $71.0 million in 2024.